GWP
ESPR

Gen-Wealth Partners’s Esperion Therapeutics ESPR Stock Holding History

Gen-Wealth Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$411 Hold
130
– – ﹤0.01% 697
2026
Q1 		$356 Hold
130
– – ﹤0.01% 704
2025
Q4 		$481 Hold
130
– – ﹤0.01% 662
2025
Q3 		$345 Hold
130
– – ﹤0.01% 664
2025
Q2 		$128 Hold
130
– – ﹤0.01% 635
2025
Q1 		$187 Hold
130
– – ﹤0.01% 607
2024
Q4 		$286 Hold
130
– – ﹤0.01% 634
2024
Q3 		$277 Hold
130
– – ﹤0.01% 646
2024
Q2 		$289 Hold
130
– – ﹤0.01% 629
2024
Q1 		$348 Buy
+130
New +$316 ﹤0.01% 611

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Gen-Wealth Partners's ESPR Position: Q2 2026 in Review

Gen-Wealth Partners held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 130 shares worth $411. The position accounts for ﹤0.01% of the portfolio, ranked #697.

Gen-Wealth Partners first reported a position in ESPR in Q1 2024 and has held it in 10 quarters since. The position peaked at $481 in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Gen-Wealth Partners held 130 shares of Esperion Therapeutics worth $411 as of Q2 2026.
  • Gen-Wealth Partners left its Esperion Therapeutics share count unchanged in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q2 2026, its #697 holding.
  • Gen-Wealth Partners first reported a position in Esperion Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Gen-Wealth Partners's Esperion Therapeutics position peaked at $481 in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.